AERIのチャート
AERIの企業情報
| symbol | AERI |
|---|---|
| 会社名 | Aerie Pharmaceuticals Inc （アエリ―・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アエリー･ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa（netarsudil点眼液）0.02％（Rhopressa）、Roclatan（netarsudil /ラタノプロスト点眼液）0.02％/ 0.005％（Roclatan）が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧（IOP）を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ（ROCK）およびノルエピネフリントランスポーター（NET）を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。 アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。 Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. |
| 本社所在地 | 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA |
| 代表者氏名 | Vicente Anido ヴィセンテ・アニード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 919-313-9650 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 160人 |
| url | www.aeriepharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aeri |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -187.08400 |
| 終値（lastsale） | 54.17 |
| 時価総額（marketcap） | 2449689445.01 |
| 時価総額 | 時価総額（百万ドル） 2406.276 |
| 売上高 | 売上高（百万ドル） 2.42300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2244.172 |
| 当期純利益 | 当期純利益（百万ドル） -186.60800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense). |
AERIのテクニカル分析
AERIのニュース
Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business 2022/11/22 10:34:20 AIThority
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority .
Aerie Pharmaceuticals last day of trading expected Nov. 18 as part of Alcon merger 2022/11/15 21:21:05 Seeking Alpha
Aerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC).
Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16, revenue of $36.1M beats by $0.8M 2022/11/03 21:06:32 Seeking Alpha
Aerie Pharmaceuticals press release (AERI): Q3 Non-GAAP EPS of -$0.27 beats by $0.16.Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M.Cash, cash equivalents, and investments were…
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results 2022/11/03 20:01:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. “Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class
Co-Chairs from Aerie Pharmaceuticals & Santen Inc USA Invite Industry Experts to join Ophthalmic Drugs 2022/10/27 10:50:56 OpenPR
The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of
Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business 2022/11/22 10:34:20 AIThority
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority .
Aerie Pharmaceuticals last day of trading expected Nov. 18 as part of Alcon merger 2022/11/15 21:21:05 Seeking Alpha
Aerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC).
Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16, revenue of $36.1M beats by $0.8M 2022/11/03 21:06:32 Seeking Alpha
Aerie Pharmaceuticals press release (AERI): Q3 Non-GAAP EPS of -$0.27 beats by $0.16.Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M.Cash, cash equivalents, and investments were…
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results 2022/11/03 20:01:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. “Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class
Co-Chairs from Aerie Pharmaceuticals & Santen Inc USA Invite Industry Experts to join Ophthalmic Drugs 2022/10/27 10:50:56 OpenPR
The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of
Aerie Pharmaceuticals Q2 2022 Earnings Preview (NASDAQ:AERI) 2022/08/03 21:35:34 Seeking Alpha
Aerie Pharmaceuticals (AERI) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.The consensus EPS Estimate is -$0.55 (compared to -$0.83 in year…
Aerie Pharma PT Lowered to $12 at Truist Securities 2022/08/01 11:22:21 Investing.com
https://www.investing.com/news/pro/aerie-pharma-pt-lowered-to-12-at-truist-securities-432SI-2859306
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET - Stocks News Feed 2022/07/29 01:10:00 Stocks News Feed
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m.… Read More »Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5: 00 p.m. ET 2022/07/28 22:10:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Is Currently -102.47 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. 2022/07/09 17:00:00 Marketing Sentinel
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)’s traded shares stood at 0.54 million during the last session, with the company’s beta value hitting 0.43. At the close of trading, the stock’s price was $8.50, to imply a decrease of -0.93% or -$0.08 in intraday trading. The AERI share’s 52-week high remains $17.21, putting it -102.47% down since that … Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Is Currently -102.47 Percent Below Its 52-Week High, But It Still Offers Strong Upside Potential. Read More »